<DOC>
	<DOC>NCT01529619</DOC>
	<brief_summary>This is a multicenter study to evaluate the efficacy, safety and tolerability of Rivastigmine patch in patients with mild to moderate Alzheimer's disease switched from Cholinesterase Inhibitors.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>A diagnosis of dementia of the Alzheimer's type according to the DSMIV criteria A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria An MMSE score of &gt; or = 10 and &lt; or = 23 Continuous treatment with donepezil ≤ 5 mg/day or galantamine ≤ 24 mg/day for 4 weeks prior to baseline visit Patients having difficulties being treated orally with ChE inhibitors (donepezil or galantamine) as judged by the investigator. Difficulties are defined as: Inadequate compliance with the ChE inhibitors at screening and baseline Presence of caregiver's burden for administering drugs orally at screening and baseline Inadequate treatment (efficacious dose cannot be reached or inadequate compliance) with the ChE inhibitors because of adverse events at screening and baseline Patients with swallowing difficulties at screening and baseline A current DSMIV diagnosis of major depression Taken rivastigmine in the past A score of &gt; 5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rivastigmine</keyword>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Transdermal patch</keyword>
</DOC>